Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model

B. Weber, P.E. Dijkman, J. Scherman, B. Sanders, M.Y. Emmert, J. Grünenfelder, R. Verbeek, M. Bracher, M. Black, T. Franz, J. Kortsmit, P. Modregger, S. Peter, M. Stampanoni, J. Robert, D. Kehl, M. Doeselaar, van, M. Schweiger, C.E. Brokopp, T. WälchliV. Falk, P. Zilla, A. Driessen - Mol, F.P.T. Baaijens, S.P. Hoerstrup

Research output: Contribution to journalArticleAcademicpeer-review

133 Citations (Scopus)
9 Downloads (Pure)

Abstract

Heart valve tissue engineering based on decellularized xenogenic or allogenic starter matrices has shown promising first clinical results. However, the availability of healthy homologous donor valves is limited and xenogenic materials are associated with infectious and immunologic risks. To address such limitations, biodegradable synthetic materials have been successfully used for the creation of living autologous tissue-engineered heart valves (TEHVs) invitro. Since these classical tissue engineering technologies necessitate substantial infrastructure and logistics, we recently introduced decellularized TEHVs (dTEHVs), based on biodegradable synthetic materials and vascular-derived cells, and successfully created a potential off-the-shelf starter matrix for guided tissue regeneration. Here, we investigate the host repopulation capacity of such dTEHVs in a non-human primate model with up to 8 weeks follow-up. After minimally invasive delivery into the orthotopic pulmonary position, dTEHVs revealed mobile and thin leaflets after 8 weeks of follow-up. Furthermore, mild-moderate valvular insufficiency and relative leaflet shortening were detected. However, in comparison to the decellularized human native heart valve control - representing currently used homografts - dTEHVs showed remarkable rapid cellular repopulation. Given this substantial in situ remodeling capacity, these results suggest that human cell-derived bioengineered decellularized materials represent a promising and clinically relevant starter matrix for heart valve tissue engineering. These biomaterials may ultimately overcome the limitations of currently used valve replacements by providing homologous, non-immunogenic, off-the-shelf replacement constructs. © 2013 Elsevier Ltd.
Original languageEnglish
Pages (from-to)7269-7280
Number of pages12
JournalBiomaterials
Volume34
Issue number30
DOIs
Publication statusPublished - 2013

Fingerprint

Dive into the research topics of 'Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model'. Together they form a unique fingerprint.

Cite this